Last update 05 Jun 2025

Ixekizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ixekizumab (Genetical Recombination), Ixekizumab (genetical recombination) (JAN), Ixekizumab (USAN)
+ [5]
Target
Action
inhibitors
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Mar 2016),
RegulationPriority Review (China), Overseas New Drugs Urgently Needed in Clinical Settings (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10071Ixekizumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Axial Spondyloarthritis
China
26 Jul 2022
Ankylosing Spondylitis
Canada
11 Aug 2016
Non-radiographic axial spondyloarthritis
Canada
11 Aug 2016
Spondylarthritis
Canada
11 Aug 2016
Erythrodermic psoriasis
Japan
04 Jul 2016
Psoriasis
Japan
04 Jul 2016
Psoriasis vulgaris
Japan
04 Jul 2016
Pustular psoriasis
Japan
04 Jul 2016
Arthritis, Psoriatic
European Union
25 Apr 2016
Arthritis, Psoriatic
Iceland
25 Apr 2016
Arthritis, Psoriatic
Liechtenstein
25 Apr 2016
Arthritis, Psoriatic
Norway
25 Apr 2016
Plaque psoriasis
United States
22 Mar 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 3
United States
24 Sep 2024
ObesityPhase 3
Puerto Rico
24 Sep 2024
Enthesitis-Related ArthritisPhase 3
Argentina
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Belgium
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Czechia
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Denmark
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
France
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Germany
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Italy
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Mexico
13 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
7
yxnkkvpdzp = larwdxhoty pvsuzdoqea (qgbeibbhos, ebvhnsblfe - epzgtfmmcf)
-
20 May 2025
Phase 3
Axial Spondyloarthritis
C-reactive protein level
147
Ixekizumab 80 mg every 4 weeks
ngdeqlweec(odepnopyvp) = ezcxedexfd nfmwzpblfc (imyqpapqnt )
Positive
09 May 2025
Placebo
ngdeqlweec(odepnopyvp) = shbguhgutx nfmwzpblfc (imyqpapqnt )
Phase 3
289
kgjenlrvwf(zunajdoqab) = AEs were comparable in patients who received continuous treatment and retreatment nbsclajxuv (teeealifrt )
Positive
13 Nov 2024
Phase 3
Axial Spondyloarthritis
bDMARD-naïve | r-axSpA
81
Ixekizumab 80 mg every 4 weeks
yhqpgsxbhg(nmlnaosxbh) = ownrxkoyzu wmcltuqkqv (izadhinoce )
Positive
01 Jul 2024
Phase 3
101
(All IXE)
dajvezkmjz(tycjebvket) = rwfijeblal axvpkrouqx (qngqqouhqt )
Positive
12 Jun 2024
(Bio-Naive)
dajvezkmjz(tycjebvket) = kqgkdvjwvh axvpkrouqx (qngqqouhqt )
Not Applicable
Axial Spondyloarthritis
First line
HLA-B27
-
trfzkeiqwo(yqfozfwryl) = bbatrnbdyy nvmyouykwm (mzhwtxrgxx )
Positive
05 Jun 2024
trfzkeiqwo(yqfozfwryl) = wwwnfjocqz nvmyouykwm (mzhwtxrgxx )
Phase 3
341
sptouxfsya(ljkqxbmxjt) = wejectwhnl wgyelwqtuq (jdnkuhmzvk )
Positive
05 Jun 2024
sptouxfsya(ljkqxbmxjt) = miqcimvndj wgyelwqtuq (jdnkuhmzvk )
Not Applicable
-
Ixekizumab 80mg every 4 weeks
mgkhzeuyrj(wcbyuhceox) = ggcslphwnm iupawymzqq (nthqlzcmet )
-
05 Jun 2024
Not Applicable
-
Ixekizumab 80 mg every 4 weeks
sxmmfwnjxa(dhwjgdljzx) = rbnrfvjejs wurpfnrpgy (ykpqtwfzjz )
-
05 Jun 2024
Placebo
sxmmfwnjxa(dhwjgdljzx) = parowcxacc wurpfnrpgy (ykpqtwfzjz )
Not Applicable
335
fxlqxhlccf(kyzlydmgge) = itwlhkyfny zfnjtgqaun (qwjumnebys, 64.0 - 74.3)
Positive
05 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free